Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis : Results from the SPARTAKUS cohort
(2019) In Rheumatology (United Kingdom) 58(7). p.1176-1187- Abstract
Objectives. To examine faecal calprotectin (F-calprotectin) levels and presence of anti-Saccharomyces cerevisiae antibodies (ASCA) and their associations with disease subtype and current status in axial SpA (axSpA). Methods. F-calprotectin and ASCA in serum were compared between consecutive patients with a clinical axSpA diagnosis, classified as non-radiographic axSpA (nr-axSpA; n = 40) or AS (n = 90), and with healthy controls (n = 35). Furthermore, standard axSpA outcome measures were compared between axSpA patients (nr-axSpA and AS combined) with elevated vs normal F-calprotectin, ASCA IgA and IgG, respectively. Results. Elevated F-calprotectin (≥50 mg/kg) was observed in 27% of nr-axSpA patients, 38% of AS patients and 6% of... (More)
Objectives. To examine faecal calprotectin (F-calprotectin) levels and presence of anti-Saccharomyces cerevisiae antibodies (ASCA) and their associations with disease subtype and current status in axial SpA (axSpA). Methods. F-calprotectin and ASCA in serum were compared between consecutive patients with a clinical axSpA diagnosis, classified as non-radiographic axSpA (nr-axSpA; n = 40) or AS (n = 90), and with healthy controls (n = 35). Furthermore, standard axSpA outcome measures were compared between axSpA patients (nr-axSpA and AS combined) with elevated vs normal F-calprotectin, ASCA IgA and IgG, respectively. Results. Elevated F-calprotectin (≥50 mg/kg) was observed in 27% of nr-axSpA patients, 38% of AS patients and 6% of controls. F-calprotectin was significantly higher in AS vs nr-axSpA [AS: geometric mean 41 (95% CI 32, 54) mg/kg; nr-axSpA: 24 (95% CI 16, 38) mg/kg; P = 0.037], and in each axSpA subtype vs controls. Overall, worse disease activity and physical function scores were observed among axSpA patients with elevated vs normal F-calprotectin levels, with significant differences regarding patient's visual analogue scale for global health, ASDAS using CRP, and BASFI (adjusted for age, sex, NSAID use, anti-rheumatic treatments, and CRP). ASCA titres and seropositivity (≥10 U/ml) were similar in nr-axSpA (IgA/IgG-seropositivity: 8%/26%) and AS (7%/28%), and clinical outcome measures did not differ between patients with elevated vs normal ASCA IgA or IgG, respectively. Compared with controls (IgA/IgG-seropositivity: 0%/17%), ASCA IgA was significantly higher in both axSpA subtypes, and IgG was significantly higher in the AS group. Conclusion. In patients with axSpA, gut inflammation measured by elevated F-calprotectin is associated with worse disease activity and physical function, and may be a marker of more severe disease.
(Less)
- author
- Olofsson, Tor LU ; Lindqvist, Elisabet LU ; Mogard, Elisabeth LU ; Andréasson, Kristofer LU ; Marsal, Jan LU ; Geijer, Mats LU ; Kristensen, Lars Erik LU and Wallman, Johan K. LU
- organization
- publishing date
- 2019-07-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Ankylosing spondylitis, Calprotectin, Gut inflammation, Inflammatory bowel disease, Non-radiographic axial spondyloarthritis, Spondyloarthritis
- in
- Rheumatology (United Kingdom)
- volume
- 58
- issue
- 7
- pages
- 12 pages
- publisher
- Oxford University Press
- external identifiers
-
- scopus:85068459267
- pmid:30649509
- ISSN
- 1462-0324
- DOI
- 10.1093/rheumatology/key427
- language
- English
- LU publication?
- yes
- id
- f8f9defd-57e2-4fed-9ff0-0340e4bb2629
- date added to LUP
- 2019-07-16 15:06:47
- date last changed
- 2024-09-18 07:03:49
@article{f8f9defd-57e2-4fed-9ff0-0340e4bb2629, abstract = {{<p>Objectives. To examine faecal calprotectin (F-calprotectin) levels and presence of anti-Saccharomyces cerevisiae antibodies (ASCA) and their associations with disease subtype and current status in axial SpA (axSpA). Methods. F-calprotectin and ASCA in serum were compared between consecutive patients with a clinical axSpA diagnosis, classified as non-radiographic axSpA (nr-axSpA; n = 40) or AS (n = 90), and with healthy controls (n = 35). Furthermore, standard axSpA outcome measures were compared between axSpA patients (nr-axSpA and AS combined) with elevated vs normal F-calprotectin, ASCA IgA and IgG, respectively. Results. Elevated F-calprotectin (≥50 mg/kg) was observed in 27% of nr-axSpA patients, 38% of AS patients and 6% of controls. F-calprotectin was significantly higher in AS vs nr-axSpA [AS: geometric mean 41 (95% CI 32, 54) mg/kg; nr-axSpA: 24 (95% CI 16, 38) mg/kg; P = 0.037], and in each axSpA subtype vs controls. Overall, worse disease activity and physical function scores were observed among axSpA patients with elevated vs normal F-calprotectin levels, with significant differences regarding patient's visual analogue scale for global health, ASDAS using CRP, and BASFI (adjusted for age, sex, NSAID use, anti-rheumatic treatments, and CRP). ASCA titres and seropositivity (≥10 U/ml) were similar in nr-axSpA (IgA/IgG-seropositivity: 8%/26%) and AS (7%/28%), and clinical outcome measures did not differ between patients with elevated vs normal ASCA IgA or IgG, respectively. Compared with controls (IgA/IgG-seropositivity: 0%/17%), ASCA IgA was significantly higher in both axSpA subtypes, and IgG was significantly higher in the AS group. Conclusion. In patients with axSpA, gut inflammation measured by elevated F-calprotectin is associated with worse disease activity and physical function, and may be a marker of more severe disease.</p>}}, author = {{Olofsson, Tor and Lindqvist, Elisabet and Mogard, Elisabeth and Andréasson, Kristofer and Marsal, Jan and Geijer, Mats and Kristensen, Lars Erik and Wallman, Johan K.}}, issn = {{1462-0324}}, keywords = {{Ankylosing spondylitis; Calprotectin; Gut inflammation; Inflammatory bowel disease; Non-radiographic axial spondyloarthritis; Spondyloarthritis}}, language = {{eng}}, month = {{07}}, number = {{7}}, pages = {{1176--1187}}, publisher = {{Oxford University Press}}, series = {{Rheumatology (United Kingdom)}}, title = {{Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis : Results from the SPARTAKUS cohort}}, url = {{http://dx.doi.org/10.1093/rheumatology/key427}}, doi = {{10.1093/rheumatology/key427}}, volume = {{58}}, year = {{2019}}, }